EGFR and non-small cell lung carcinoma: According to the Phase I U31402‐A‐U102 study, HER3‐DXd achieved an ORR of 39%, a DCR of 68%, and a median PFS of 8.2 months in patients with advanced EGFR‐mutated NSCLC who had previously received osimertinib and platinum‐based chemotherapy.